AKT1 Program

About Terremoto Biosciences

Terremoto Biosciences, founded in 2021 and based in San Diego, is a well-funded private biotech leveraging a proprietary covalent chemistry platform to develop novel small-molecule drugs. The company has a strong leadership team with deep experience in covalent drug discovery, notably from Principia Biotech, and has raised significant capital from top-tier investors like OrbiMed and Third Rock Ventures. Its initial focus is on a precision oncology program targeting AKT1 mutations, with the broader platform enabling pursuit of both best-in-class and first-in-class medicines against challenging targets.

About Terremoto Biosciences

Terremoto Biosciences, founded in 2021 and based in San Diego, is a well-funded private biotech leveraging a proprietary covalent chemistry platform to develop novel small-molecule drugs. The company has a strong leadership team with deep experience in covalent drug discovery, notably from Principia Biotech, and has raised significant capital from top-tier investors like OrbiMed and Third Rock Ventures. Its initial focus is on a precision oncology program targeting AKT1 mutations, with the broader platform enabling pursuit of both best-in-class and first-in-class medicines against challenging targets.

Therapeutic Areas